Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177787
Title: | Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study |
Author: | Pérez de José, Ana Carbayo, Javier Pocurull, Anna Bada Bosch, Teresa Cases Corona, Clara Maria Shabaka, Amir Ramos Terrada, Natàlia Martínez Valenzuela, Laura Huerta, Ana Fernandez Lorente, Loreto Malek Marín, Tamara Gelen Goicoechea, Marian |
Keywords: | Hepatitis C Malalties del ronyó Hepatitis C Kidney diseases |
Issue Date: | 25-Jan-2020 |
Publisher: | Oxford University Press |
Abstract: | Background: Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods: The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results: Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70-251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04-0.40]; P < 0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04-0.33); P < 0.001]. Conclusions: Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality. |
Note: | Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfz178 |
It is part of: | Clinical Kidney Journal, 2020, vol. 14, num. 2, p. 586-592 |
URI: | http://hdl.handle.net/2445/177787 |
Related resource: | https://doi.org/10.1093/ckj/sfz178 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sfz178.pdf | 454.65 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License